Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 21;14(1):151.
doi: 10.1186/s13098-022-00920-y.

The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials

Elham Razmpoosh  1 , Shima Abdollahi  2 , Mahdieh Mousavirad  3 , Cain C T Clark  4 , Sepideh Soltani  5
Affiliations
Review

The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials

Elham Razmpoosh et al. Diabetol Metab Syndr. .

Abstract

Background: The aim of this systematic review and meta-analysis was to determine the effect of olive leaf extract (OLE) supplementation on cardiovascular-related variables, including lipid, glycemic, inflammatory, liver and renal-related factors, as well as blood pressure.

Methods: PubMed, ISI Web of Science, Scopus, and Cochrane library were searched, up to October 2021, for relevant controlled trials. Mean differences and standard deviations were pooled for all outcomes, using a random-effects model. The methodological quality, as well as quality of evidence were assessed using standard tools.

Results: Twelve studies (n = 819 participants) were included in our analyses. Overall analyses showed that OLE supplementation significantly decreased triglyceride (TG) levels (WMD = - 9.51 mg/dl, 95% CI - 17.83, - 1.18; P = 0.025; I2 = 68.7%; P-heterogeneity = 0.004), and systolic blood pressure (SBP) (WMD = - 3.86 mmHg, 95% CI - 6.44, - 1.28 mmHg; P = 0.003; I2 = 19.9%; P-heterogeneity = 0.28). Subgroup analyses also revealed a significant improvement in SBP (- 4.81 mmHg) and diastolic blood pressure (- 2.45 mmHg), TG (- 14.42 mg/dl), total cholesterol (TC) (- 9.14 mg/dl), and low-density lipoprotein-C (LDL-C) (- 4.6 mg/dl) measurements, in patients with hypertension. Significant reductions were also observed in TC (- 6.69 mg/dl), TG (- 9.21 mg/dl), and SBP (- 7.05 mmHg) in normal-weight individuals. However, no meaningful changes were seen in glucose hemostasis, liver and kidney, or inflammatory markers.

Conclusion: The present study revealed that supplementation with OLE yielded beneficial effects for blood pressure and lipid profile in adults, especially in patients with hypertension. As the quality of evidence for glucose hemostasis variables, liver, kidney, and inflammatory markers, were low-to-very low, higher quality RCTs may impact the overarching results. This study was registered at PROSPERO with the code CRD42022302395.

Keywords: Blood pressure; Cardiovascular diseases; Meta-analysis; Olive leaf extract; Systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram for the study selection process
Fig. 2
Fig. 2
Forest plot of randomized controlled trials (RCTs) illustrating weighted mean differences in a total cholesterol, b LDL-c, c HDL-c, and d triglyceride between OLE supplementation and control groups for all eligible studies. Analysis was conducted using a random effects model
Fig. 3
Fig. 3
Forest plot of randomized controlled trials (RCTs) illustrating weighted mean differences in a FBS, b HbA1c, c HOMA-IR, and d insulin levels between OLE supplementation and control groups for all eligible studies. Analysis was conducted using a random effects model
Fig. 4
Fig. 4
Forest plot of randomized controlled trials (RCTs) illustrating weighted mean differences in a SBP, and b DBP between OLE supplementation and control groups for all eligible studies. Analysis was conducted using a random effects model
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. WHO. World Health Organization (WHO): noncommunicable diseases 2021. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-disease.... Accessed Apr 2021.
    1. Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart Views. 2017;18:109–114. - PMC - PubMed
    1. Budreviciute A, Damiati S, Sabir DK, Onder K, Schuller-Goetzburg P, Plakys G, et al. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Front Public Health. 2020;8:574111. - PMC - PubMed
    1. Flora GD, Nayak MK. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr Pharm Des. 2019;25:4063–4084. - PubMed
    1. Donia T, Khamis A. Management of oxidative stress and inflammation in cardiovascular diseases: mechanisms and challenges. Environ Sci Pollut Res. 2021;28:34121–34153. - PubMed